Log in
Enquire now
‌

US Patent 7736848 Cellular targets for treatment of retroviral infection

Patent 7736848 was granted and assigned to Fox Chase Cancer Center (company) on June, 2010 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Current Assignee
Fox Chase Cancer Center (company)
Fox Chase Cancer Center (company)
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
77368480
Patent Inventor Names
Roger J. Pomerantz0
Gary D. Kao0
Giuseppe Nunnari0
Rene Daniel0
Anna Marie Skalka0
Date of Patent
June 15, 2010
0
Patent Application Number
110936920
Date Filed
March 30, 2005
0
Patent Primary Examiner
‌
Larry R. Helms
0
Patent abstract

Cellular targets for anti-retroviral drug development are disclosed. The cellular targets comprise ATR kinase and its relevant substrates, based on the identification of the ATR kinase as required for the final step of retroviral DNA integration. Assays for identifying modulators of retroviral integration via the ATR kinase pathway are disclosed, as well as modulators identified by such assays. Pharmaceutical preparations and methods of their use in treating retroviral infection are also disclosed.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 7736848 Cellular targets for treatment of retroviral infection

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.